Seek Returns logo

VTRS vs. WAT: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at VTRS and WAT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolVTRSWAT
Company NameViatris Inc.Waters Corporation
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsLife Sciences Tools & Services
Market Capitalization12.30 billion USD17.79 billion USD
ExchangeNasdaqGSNYSE
Listing DateMarch 17, 1980November 17, 1995
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of VTRS and WAT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

VTRS vs. WAT: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolVTRSWAT
5-Day Price Return-1.22%0.41%
13-Week Price Return24.12%-14.21%
26-Week Price Return-3.48%-20.91%
52-Week Price Return-9.83%-11.05%
Month-to-Date Return20.71%3.53%
Year-to-Date Return-15.26%-19.42%
10-Day Avg. Volume8.78M0.59M
3-Month Avg. Volume12.06M0.69M
3-Month Volatility31.14%38.80%
Beta0.911.06

Profitability

Return on Equity (TTM)

VTRS

-19.92%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

WAT

35.02%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

WAT’s Return on Equity of 35.02% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

VTRS vs. WAT: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

VTRS

-24.57%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

WAT

21.71%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

A Net Profit Margin of 21.71% places WAT in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.

VTRS vs. WAT: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

VTRS

-26.54%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

WAT

27.69%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

An Operating Profit Margin of 27.69% places WAT in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

VTRS vs. WAT: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolVTRSWAT
Return on Equity (TTM)-19.92%35.02%
Return on Assets (TTM)-8.50%14.40%
Net Profit Margin (TTM)-24.57%21.71%
Operating Profit Margin (TTM)-26.54%27.69%
Gross Profit Margin (TTM)40.15%59.02%

Financial Strength

Current Ratio (MRQ)

VTRS

1.37

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

WAT

1.75

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

WAT’s Current Ratio of 1.75 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.

VTRS vs. WAT: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

VTRS

0.82

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

WAT

0.67

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

WAT’s Debt-to-Equity Ratio of 0.67 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

VTRS vs. WAT: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

VTRS

-0.13

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

WAT

11.29

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

WAT’s Interest Coverage Ratio of 11.29 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.

VTRS vs. WAT: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolVTRSWAT
Current Ratio (MRQ)1.371.75
Quick Ratio (MRQ)0.651.22
Debt-to-Equity Ratio (MRQ)0.820.67
Interest Coverage Ratio (TTM)-0.1311.29

Growth

Revenue Growth

VTRS vs. WAT: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

VTRS vs. WAT: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

VTRS

4.58%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

WAT

0.00%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

WAT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

VTRS vs. WAT: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

VTRS

137.04%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

WAT

0.00%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

WAT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

VTRS vs. WAT: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolVTRSWAT
Dividend Yield (TTM)4.58%0.00%
Dividend Payout Ratio (TTM)137.04%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

VTRS

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for VTRS is currently unavailable.

WAT

26.76

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

In the lower quartile for the Life Sciences Tools & Services industry, WAT’s P/E Ratio of 26.76 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

VTRS vs. WAT: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

VTRS

0.88

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

WAT

5.81

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

WAT’s P/S Ratio of 5.81 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

VTRS vs. WAT: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

VTRS

0.67

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

WAT

9.62

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

At 9.62, WAT’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

VTRS vs. WAT: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolVTRSWAT
Price-to-Earnings Ratio (TTM)--26.76
Price-to-Sales Ratio (TTM)0.885.81
Price-to-Book Ratio (MRQ)0.679.62
Price-to-Free Cash Flow Ratio (TTM)7.2928.57